Evolutionary Genomics Inc (FNAM) Earnings Report, Financial Results, Financial analysis

Evolutionary Genomics Inc narrowed forth quarter of 2022 net loss per share of $-0.06 compare to net loss per share of $-0.40 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.09 realized in previous quarter.

*forth quarter of 2022*
Earnings Per Share	Revenues
$ -0.06	$ 0 Mill
$+0.34	Unch.

Evolutionary Genomics Inc 's Revenue fell by 0 % in forth quarter of 2022 (Dec 31 2022) year on year, to $0 million and declined by sequentially.

Evolutionary Genomics Inc is Expected to report next financial results on March 08, 2024.

More on FNAM's Income Statement

FNAM's NET INCOME

Evolutionary Genomics Inc 's in theforth quarter of 2022 recorded net loss of $-0.334 million, an improvement compare to net loss of $-2.262 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-0.545 million realized in previous quarter.

More on FNAM's Growth

Evolutionary Genomics Inc Inventories
In Dec 31 2022 company's net cash and cash equivalents decreased by $0 million

Earnings quality

Evolutionary Genomics Inc does not pay out common stock dividend.

In trailing twelve-month period Evolutionary Genomics Inc payed $ -0.10 cash per share, on a free-cash flow basis .

Tangible Book value fell to $ -1.13 per share from $ -1.07.

Company repurchased 0.23 million shares or 3.48 % in Dec 31 2022.

• More on FNAM's Dividends

Market Capitalization (Millions)	5
Shares Outstanding (Millions)	6
Total Debt (Millions $)	4
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-2
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Evolutionary Genomics Inc does not pay out common stock dividend.

In trailing twelve-month period Evolutionary Genomics Inc had negative $ -0.10 cash flow per share, on a free-cash flow basis .

Tangible Book value fell to $ -1.13 per share from $ -1.07.

Company repurchased 0.23 million shares or 3.48 % in Dec 31 2022.

• More on FNAM's Balance Sheets

Market Capitalization (Millions)	5
Shares Outstanding (Millions)	6
Total Debt (Millions $)	4
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-2
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Evolutionary Genomics Inc

FNAM's Financial Statements and Analysis